Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. GIP-induced vasodilation in human adipose tissue involves capillary recruitment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mitochondrial mutation m.3243A>G associates with insulin resistance in non-diabetic carriers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cross-sectional analysis of sleep hours and quality with sex hormones in men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Increases in bioactive IGF do not parallel increases in total IGF-I during growth hormone treatment of children born SGA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Measurement of peripheral arterial tonometry in patients with diabetic foot ulcers during courses of hyperbaric oxygen treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A Polygenic Risk Score Suggests Shared Genetic Architecture of Voice Break With Early Markers of Pubertal Onset in Boys

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The External Genitalia Score (EGS): A European multicenter validation study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Gudmundur Johannsson
  • Martin Bidlingmaier
  • Beverly Biller
  • Margaret Boguszewski
  • Felipe F Casanueva
  • Philippe Chanson
  • Catherine S Choong
  • Peter E Clayton
  • David Clemmons
  • Mehul Dattani
  • Jan Frystyk
  • Ken K Y Ho
  • Andrew Hoffman
  • Reiko Horikawa
  • Anders Juul
  • John Kopchick
  • Xiaoping Luo
  • Sebastian Neggers
  • Irène Netchine
  • Daniel S Olsson
  • Sally Radovick
  • Ron G Rosenfeld
  • Richard J Ross
  • Katharina Schilbach
  • Paulo Ferrez Collett-Solberg
  • Christian J Strasburger
  • Peter J Trainer
  • Kerstin Wickstrom
  • Kevin Cj Yuen
  • Jens Otto Lunde Jørgensen
Vis graf over relationer

OBJECTIVE: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults, and in patients with acromegaly.

PARTICIPANTS: GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry.

EVIDENCE: Current literature was reviewed and expert opinion was utilized to establish the state of the art, and identify current gaps and unmet needs.

CONSENSUS PROCESS: Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process.

CONCLUSIONS: The clinical endpoint in pediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of co-morbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.

OriginalsprogEngelsk
TidsskriftEndocrine Connections
Vol/bind7
Udgave nummer3
Sider (fra-til)R126-R134
ISSN2049-3614
DOI
StatusUdgivet - 2018

ID: 53311933